Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

Revolution Medicines attracted takeover interest but decided to go it alone. This week's FDA approval of its pancreatic cancer pill is the payoff.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。